Overview

Combined Anticancer Treatment of Advanced Colon Cancer

Status:
Terminated
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The COMBATAC study evaluates the the effect as assessed by progression-free survival (PFS) of perioperative systemic chemotherapy including cetuximab and cytoreductive surgery (CRS) and bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from colorectal cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Regensburg
Collaborator:
Heinrich-Heine University, Duesseldorf
Treatments:
Cetuximab